Immunoglobulin light chains: Difference between revisions
From haematologyetc.co.uk
(Created page with " <div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;"> :<span style="color:navy">'''Summary'''</span> :xxxx </div> <span style="color:navy">'''Normal expression and function'''</span> xxxxx <span style="color:navy">'''Diagnostic role'''</span> *xxxxx <span style="color:navy">'''Other relevant information:'''</span> xxxxx ---- <span style="color:navy">'''''SUMMARY TABLES'''''</span> <span style="font-...") |
No edit summary |
||
Line 5: | Line 5: | ||
:<span style="color:navy">'''Summary'''</span> | :<span style="color:navy">'''Summary'''</span> | ||
: | :Immunoglobulin light chains are part of the B-cell receptor and can therefore be considered as a pan B-cell marker - expressed from late lymphoblast stage until plasma cell differentiation. | ||
:If cells express predomnantly kappa or lambda (light chain restriction) then clonality can be inferred. | |||
Revision as of 18:15, 27 May 2023
- Summary
- Immunoglobulin light chains are part of the B-cell receptor and can therefore be considered as a pan B-cell marker - expressed from late lymphoblast stage until plasma cell differentiation.
- If cells express predomnantly kappa or lambda (light chain restriction) then clonality can be inferred.
Normal expression and function
xxxxx
Diagnostic role
- xxxxx
Other relevant information:
xxxxx
SUMMARY TABLES
Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name
Expression in primitive cell types | |||||||
---|---|---|---|---|---|---|---|
AML | CMML | B ALL | Burkitt | T ALL | ETP ALL <I> | MPAL <I> | Hgns <I> |
? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
Expression in mature B cell neoplasms | |||||||
---|---|---|---|---|---|---|---|
CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
Expression in mature T cell neoplasms* | ||||||
---|---|---|---|---|---|---|
ATLL | CTCL/Sezary | T-PLL | T-LGL | NK-LGL | ||
? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx